Impact of drug price adjustments on utilization of and expenditures on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in Taiwan

BMC Public Health

Thau-Ming Cham²  Shu-Hui Yu³  Chien-Ning Hsu¹  Shiou-Huei Huang² 

[1] Graduate Institute of Clinical Pharmacy, College of Pharmacy, Kaohsiung Medical University, No. 100, Shih-Chuan 1st Road, Kaohsiung, 807, Taiwan;School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, No. 100, Shih-Chuan 1st Road, Kaohsiung, 807, Taiwan;Institute of Statistics, National University of Kaohsiung, No. 700, Kaohsiung University Road, Nanzih District, 811, Kaohsiung, Taiwan

关键词: Drug expenditures;    Drug utilization;    Off-patent drug;    Patented drug;    Prescription switching;    Brand-name drug;    Generic drug;    Drug price adjustments;   

Others  :  1163687
DOI  :  10.1186/1471-2458-12-288

 received in 2011-09-27, accepted in 2012-04-20,  发布年份 2012

【 摘 要 】

Background

A previous study has suggested that drug price adjustments allow physicians in Taiwan to gain greater profit by prescribing generic drugs. To better understand the effect of price adjustments on physician choice, this study used renin-angiotensin drugs (including angiotensin-converting enzyme inhibitors [ACEIs] and angiotensin receptor blockers [ARBs]) to examine the impact of price adjustments on utilization of and expenditures on patented and off-patent drugs with the same therapeutic indication.

Methods

Using the Taiwan’s Longitudinal Health Insurance Database (2005), we identified 147,157 patients received ACEIs and/or ARBs between 1997 and 2008. The annual incident and prevalent users of ACEIs, ARBs and overall renin-angiotensin drugs were examined. Box-Tiao intervention analysis was applied to assess the impact of price adjustments on monthly utilization of and expenditures on these drugs. ACEIs were divided into patented and off-patent drugs, off-patent ACEIs were further divided into original brands and generics, and subgroup analyses were performed.

Results

The number of incident renin-angiotensin drug users decreased over the study period. The number of prevalent ARB users increased and exceeded the cumulative number of first-time renin-angiotensin drug users starting on ARBs, implying that some patients switched from ACEIs to ARBs. After price adjustments, long term trend increases in utilization were observed for patented ACEIs and ARBs; a long-term trend decrease was observed for off-patent ACEIs; long-term trend change was not significant for overall renin-angiotensin drugs. Significant long-term trend increases in expenditures were observed for patented ACEIs after price adjustment in 2007 (200.9%, p = 0.0088) and in ARBs after price adjustments in 2001 (173.4%, p < 0.0001) and 2007 (146.3%, p < 0.0001). A significant long-term trend decrease in expenditures was observed for off-patent ACEIs after 2004 price adjustment (−156.9%, p < 0.0001). Expenditures on overall renin-angiotensin drugs showed long-term trend increases after price adjustments in 2001 (72.2%, p < 0.0001) and 2007 (133.4%, p < 0.0001).

Conclusions

Price adjustments did not achieve long-term cost savings for overall renin-angiotensin drugs. Possible switching from ACEIs to ARBs within individuals is evident. Policy makers should reconsider the appropriateness of the current adjustment strategies applied to patented and off-patent drugs.

【 授权许可】

   
2012 Huang et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1][http:/ / www.nhi.gov.tw/ resource/ Webdata/ 13767_1_NHI%20IN%20TAIWAN%202011%20 ANNUAL%20REPORT.pdf] webciteNational Health Insurance in Taiwan 2011 Annual Report.
• [2]Chou YJ, Yip WC, Lee CH, Huang N, Sun YP, Chang HJ: Impact of separating drug prescribing and dispensing on provider behaviour: Taiwan’s experience. Health Policy Plan 2003, 18(3):316-329.
• [3]Cheng TM: Taiwan’s new national health insurance program: genesis and experience so far. Health Aff (Millwood) 2003, 22(3):61-76.
• [4][http://www.nhi.gov.tw/english/webdata.asp?menu=11&menu_id=295&webdata_id=2444] webciteGuidelines of price adjustment for National Health Insurance reimbursed drugs.
• [5]Lee YC, Yang MC, Huang YT, Liu CH, Chen SB: Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996–2003. PharmacoEconomics 2006, 24(9):891-902.
• [6]Liu YM, Yang YH, Hsieh CR: Financial incentives and physicians’ prescription decisions on the choice between brand-name and generic drugs: evidence from Taiwan. J Health Econ 2009, 28(2):341-349.
• [7]National High Blood Pressure Education Program: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute, Bethesda, MD; 2004.
• [8]National Health Insurance Research Database (NHIRD): . [http://w3.nhri.org.tw/nhird/en/index.htm] webcite Taiwan
• [9][http://www.nhi.gov.tw] webciteBureau of National Health Insurance (BNHI), Taiwan.
• [10]World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology: ATC/DDD index[http://www.whocc.no] webcite Norwegian Institute of Public Health
• [11]Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288(21):2709-2716.
• [12]Box GEP, Tiao GC: Intervention analysis with applications to economic and enviromental problems. J Am Stat Assoc 1975, 70:70-79.
• [13]SAS Institute Inc: SAS ETS® User’s Guide, 9.1 Version. SAS Institute Inc, Cary, NC; 2004.
• [14]Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D: Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002, 27(4):299-309.
• [15]Chou CC, Hu KY, Wu NR, Cheng YH, Loh CH, Yeh MK: Changes in drug prescription utilization for diabetic and hypertensive outpatients after initiation of the National Health Insurance’s Global Budget Program in Taiwan. Med Sci Monit 2008, 14(5):PH33-PH39.
• [16]Liu LM: Analysis of time series with calendar effects. Manage Sci 1980, 26(1):106-112.
• [17]Kleinbaum DG, Kupper LL, Muller KE: Applied regression analysis and other multivariable methods. PWS Kent Publishing Company, Boston; 1988.
• [18]Aaserud M, Dahlgren AT, Kösters JP, Oxman AD, Ramsay C, Sturm H: Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev 2006., (2006, Issue 2. Art. No.: CD005979)
• [19]Rigter H: Recent public policies in The Netherlands to control pharmaceutical pricing and reimbursement. PharmacoEconomics 1994, 6(Suppl 1):15-21.
• [20]Ess SM, Schneeweiss S, Szucs TD: European healthcare policies for controlling drug expenditure. PharmacoEconomics 2003, 21(2):89-103.
• [21]Kaló Z, Muszbek N, Bodrogi J, Bidló J: Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Health Policy 2007, 80(3):402-412.
• [22]Liberman JN, Roebuck MC: Prescription drug costs and the generic dispensing ratio. J Manag Care Pharm 2010, 16(7):502-506.
• [23]Gibson TB, McLaughlin CG, Smith DG: Generic utilization and cost-sharing for prescription drugs. Adv Health Econ Health Serv Res 2010, 22:195-219.
• [24]Rizzo JA, Zeckhauser R: Generic script share and the price of brand-name drugs: the role of consumer choice. Int J Health Care Finance Econ 2009, 9(3):291-316.
• [25]Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani HB, et al.: Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension. Curr Med Res Opin 2010, 26(4):849-860.